期刊
INTERNATIONAL JOURNAL OF UROLOGICAL NURSING
卷 3, 期 3, 页码 85-92出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-771X.2009.01081.x
关键词
Androgen deprivation; Degarelix; Gonadotrophin-receptor blocker; Hormonal therapy; Prostate cancer
资金
- Ferring Pharmaceuticals
The development of GnRH blockers provides a new class of hormonal agent with a different, direct mode of action. Degarelix, a newly approved GnRH blocker, has displayed a fast, profound and sustained suppression of testosterone and prostate-specific antigen levels without subsequent tumour flare effects. This paper considers the current evidence for this new treatment approach and how this may impact on current urology nursing practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据